Evaxion Biotech A/S
Evaxion Biotech A/S
Your view on EVAX
Overview
What the company does, where it operates, and who runs it.
About Evaxion Biotech A/S
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Birgitte Rono
- Headquarters
- Dr. Neergaards Vej, Horsholm, DK
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Birgitte Rono
- Headquarters
- Dr. Neergaards Vej, Horsholm, DK
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections.
The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers.
Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Evaxion Biotech A/S, and the rating behind it. EVAX last traded at $3.13; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Evaxion Biotech A/S. Starting points for Evaxion Biotech A/S: EPS -$20.75, beta 0.27 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Evaxion Biotech A/S. Evaxion Biotech A/S does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Evaxion Biotech A/S. Trailing twelve-month EPS for Evaxion Biotech A/S stands at -$20.75. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Evaxion Biotech A/S. Evaxion Biotech A/S has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Evaxion Biotech A/S valued side by side against its closest peers. Evaxion Biotech A/S is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Evaxion Biotech A/S, and how their positions are changing. At a $19.8M market value, institutional positions materially move Evaxion Biotech A/S's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Evaxion Biotech A/S executives and directors. Shares of Evaxion Biotech A/S have traded between $1.20 and $12.15 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Evaxion Biotech A/S. Evaxion Biotech A/S is a $19.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Evaxion Biotech A/S. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Evaxion Biotech A/S. Coverage tracks Evaxion Biotech A/S within Biotechnology (Healthcare). Press releases and market coverage, newest first.